Clinical Evaluation of GRAPE Model for Gastric Cancer Screening
NCT ID: NCT07067983
Last Updated: 2025-07-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000000 participants
OBSERVATIONAL
2025-05-30
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer
NCT04989153
Early Detection and Screening Strategy of Gatric Cancer in Sichuan Province-A Prospective Cohort Study (WCH-GC-SIGES-01)
NCT03597672
A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening
NCT07032961
An Observational Study for Gastric Cancer in Asymptomatic Carriers of High Risk Helicobacter Pylori
NCT06896370
Screening for Early Gastric Cancer in Shaanxi Province
NCT05291728
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Results following systematic screening
The GRAPE model's output (positive or negative) determines whether patients require follow-up gastroscopy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals undergoing thoracoabdominal CT examination
* Voluntarily participated in the study and provided written informed consent
Exclusion Criteria
* Individuals with severe intellectual disabilities or communication disorders
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhejiang Cancer Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiangdong Cheng
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiangdong Cheng
Role: PRINCIPAL_INVESTIGATOR
Zhejiang Cancer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIT-2025-160
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.